#PLRX

1 month ago

#PLRX seeing new positions from large shareholders, strong institutional ownership and undervalued as a small biotech company

0 0 0 0

1 month ago

Today’s most trending tickers with positive sentiment (last 24h):

#SPY: 20
#BTC: 13
#AAPL: 11
#NXXT: 11
#AMZN: 11
#HIMS: 11
#MSFT: 9
#COIN: 8
#ORCL: 7
#TSLA: 6
#VTGN: 6
#QQQ: 6
#GOOGL: 6
#NIO: 5
#PLRX: 5
#MU: 5
#GS: 5
#RUM: 5

0 0 0 0

1 month ago

#PLRX gets a boost as GSA Capital increases stake by 287%, trading at bargain prices 50% below cash levels.

0 0 0 0

1 month ago

Today’s most trending tickers with positive sentiment (last 24h):

#AMZN: 39
#BTC: 25
#SPY: 19
#NVDA: 17
#MSTR: 16
#MSFT: 15
#GS: 15
#TSLA: 13
#RDDT: 10
#RBLX: 9
#DIA: 9
#NUKK: 8
#QQQ: 8
#PLRX: 7
#ASTS: 7
#NFLX: 6
#RIME: 6
#BILL: 6

0 0 0 0

2 months ago

#PLRX primed for vertical run, potentially reaching $1.7 after breaking above $1.35.

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#NVDA: 25
#TSLA: 20
#AAPL: 17
#INTC: 15
#SPY: 14
#BYND: 13
#OPEN: 13
#ASTS: 13
#EOSE: 11
#NXXT: 11
#AMZN: 11
#RKLB: 10
#IPO: 9
#GOOGL: 8
#QQQ: 8
#GOOG: 8
#PLRX: 7
#BTC: 7

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#NVDA: 43
#SPY: 18
#TSLA: 15
#ASTS: 13
#EOSE: 10
#ZETA: 9
#ONDS: 9
#OPEN: 9
#OKLO: 8
#NVIDIA: 7
#CVX: 7
#RIME: 7
#MSTR: 7
#AMD: 6
#AMZN: 6
#ALMS: 5
#PLRX: 5
#RKLB: 5

0 0 0 1

2 months ago

#PLRX trading below cash value with potential for a move in January, backed by high open interest for Jan calls.

0 0 0 0

2 months ago

Today’s most cited tickers with positive sentiment (last 24h):

#TSLA: 54
#MU: 18
#YCBD: 15
#AMZN: 14
#SPY: 12
#COIN: 11
#NFLX: 9
#ORCL: 8
#MDLN: 8
#NVDA: 7
#GOOGL: 6
#VTGN: 6
#SLV: 5
#QCLS: 5
#AAPL: 5
#PLRX: 4

#StockstoWatch #StockstoBuy

0 0 0 0

2 months ago

#PLRX gets new COO, trading at bargain prices with institutions holding big stakes. High OI for Jan16 2026 and price targets above current price. #StocksToWatch #StocksToBuy #Biotech

0 0 0 0

2 months ago

Today’s most cited tickers with positive sentiment (last 24h):

#TSLA: 77
#FLWS: 13
#PYPL: 11
#SPY: 11
#QCLS: 10
#AVGO: 8
#AAPL: 7
#PLRX: 7
#BEAT: 6
#AMCI: 6
#AMZN: 5
#NFLX: 5
#TLT: 5
#ORCL: 5
#AEO: 5
#SRXH: 5

#StockstoWatch #StockstoBuy

0 0 0 0

2 months ago

#PLRX trading at bargain prices with strong institutions holding big stakes. Easy money to be made? #StocksToWatch #StocksToBuy #Biotech

0 0 1 0

2 months ago

Today’s most cited tickers with positive sentiment (last 24h):

#TSLA: 31
#FLWS: 12
#SPY: 10
#PYPL: 9
#AMCI: 8
#AVGO: 7
#GME: 5
#RIVN: 5
#BTC: 5
#JPM: 5
#BMNR: 4
#LLY: 4
#SRPT: 4
#PLRX: 4
#ARTV: 4
#AAPL: 4

#StockstoWatch #StockstoBuy

0 0 0 0

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks with strong volume declines, Thu Dec 4th - #YB #NA #MAMO #LASE #DRMA #CNTX #SYBX #SVCO #PLRX #NDRA #KITT #EKSO #CBIO #BBNX #ZKH #NOAH #GCO #ECVT #BBW - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors Pliant Therapeutics (NASDAQ: PLRX) reported interim Phase 1 dose-escalation data for oral PLN-101095 combined with pembrolizumab in ICI-refractory advanced/metastatic solid tumors dated Dec 4, 2025. In the three highest dose cohorts, 4 responders were observed among 10 secondary ICI-refractory patients (1 confirmed CR, 2 confirmed PR, 1 unconfirmed PR). Median time on treatment for responders was 15 months as of Nov 30, 2025. 60% of secondary refractory patients showed stable disease or tumor reduction. Responders had 4- to 13-fold increases in plasma IFN-γ after 14-day PLN-101095 monotherapy. Drug was generally well tolerated with 2 discontinuations. Company plans a Phase 1b expansion in 2026 and says cash supports operations through 2028.

3 months ago

#PLRX Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Most Searched, Wednesday November 26, 2025 – Crystal Equity Research

3 months ago

Most searched small-cap stocks, Wed Nov 26th - #HIVE #NVTS #SMX #DVLT #UPWK #CETY #BTBT #DNN #SPRC #RR #UUUU #RMAX #PLRX #ONDS #LAC #GPUS #CLSK #BYND #AEHL - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Pliant Therapeutics (Nasdaq: PLRX) provided a corporate update and reported third quarter 2025 results on Nov 6, 2025. The company completed enrollment in the Phase 1 open-label trial of PLN-101095 in solid tumors; interim data showed a 50% objective response rate in one dose cohort and full trial data, including the two highest dose cohorts, are expected by the end of 2025. Close out activities for the BEACON‑IPF Phase 2b/3 trial are expected to finish in Q4 2025, with full results planned for future publication. In October the company completed a voluntary prepayment of its March 11, 2024 loan with Oxford Finance. Q3 2025 results: R&D $17.9M (prior $47.8M), G&A $10.3M (prior $14.3M), Net loss $26.3M (prior $57.8M), and Cash & short-term investments $243.3M as of Sept 30, 2025.

4 months ago

#PLRX Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Pliant Therapeutics Provides Update on BEACON-IPF Pliant Therapeutics (NASDAQ:PLRX) announced the discontinuation of bexotegrast development for idiopathic pulmonary fibrosis (IPF) following unfavorable results from the BEACON-IPF Phase 2b/3 trial. The trial was terminated due to an imbalance in IPF-related adverse events, with bexotegrast-treated participants showing increased risk of disease progression.Despite initial improvements in forced vital capacity (FVC) at Week 12, the drug demonstrated an unfavorable risk-benefit profile at both 160mg and 320mg doses. The company continues to advance its clinical oncology program, with PLN-101095 showing promising interim results in Phase 1 trials, including 50% partial response rates in the highest dose cohort.

8 months ago

#PLRX Pliant Therapeutics Provides Update on BEACON-IPF

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

8 months ago

Small-cap stocks in new downtrend in Average Directional Index, Mon Jun 23rd - #TELO #PRFX #DTST #TALK #SJ #RVPH #PLRX #CERT #BTCT #ATOM #WGO #NL #MLNK #HBI #BCSF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference Pliant Therapeutics (PLRX) presented clinical and preclinical data at the American Thoracic Society 2025 International Conference, highlighting three key studies on their drug bexotegrast. The first study showed that bexotegrast, a dual inhibitor of αVβ6/αVβ1 integrins, reduced fibrosis-related gene expression in lung cells from non-IPF ILD patients. A second study identified biomarkers across different ILD subtypes that could help inform clinical decisions. The third study demonstrated bexotegrast's distinct antifibrotic effects, showing superior results compared to nintedanib in reducing profibrotic genes in specific cell types, both alone and in combination therapy.

9 months ago

#PLRX Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Pliant Therapeutics (NASDAQ: PLRX) reported Q1 2025 financial results and provided corporate updates. The company is finalizing its BEACON-IPF Phase 2b/3 trial with topline data expected in Q2 2025. Their oncology program showed promising results, with PLN-101095 demonstrating antitumor activity in combination with pembrolizumab, achieving confirmed partial responses in 3 out of 6 patients at the highest dose tested. The company announced a strategic realignment including a 45% workforce reduction to extend cash runway. Financial results showed R&D expenses of $43.4M (up from $37.1M YoY), G&A expenses of $15.5M, and a net loss of $56.2M (compared to $47.0M YoY). As of March 31, 2025, Pliant maintained a strong cash position of $307.1M in cash, cash equivalents, and short-term investments.

10 months ago

#PLRX Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results Major restructuring at Pliant preserves cash for late-stage IPF drug trial. Company maintains clinical operations despite 45% staff reduction. See strategic impact.

10 months ago

#PLRX Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Breakthrough: New Cancer Drug Achieves 74% Tumor Reduction in Phase 1 Study Pliant's PLN-101095 demonstrates 74% tumor reduction in lung cancer and strong results in other solid tumors. Early data shows promise for treatment-resistant cancers.

11 months ago

#PLRX Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan Biotech firm implements stockholder rights plan limiting ownership to 10% amid recent stock accumulations. Board retains control over $0.001 per right redemption option.

1 year ago

#PLRX Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #PLRX ) Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #PLRX ) Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

1 year ago

Most searched small-cap stocks, Mon Mar 3rd - #BBAI #BTE #WULF #BB #APLD #RXRX #WOLF #QS #PLRX #PTEN #ACON #MKTW #QBTS #RGTI #SMR #SSYS #TRNR #UEC #UUUU #BTAI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Pliant's IPF Trial Halted on Safety Concerns: What's Next for Their $357M Pipeline? Safety concerns halt BEACON-IPF trial despite early efficacy signals. Company pivots to oncology and muscular dystrophy programs with $357.2M cash runway.

1 year ago

#PLRX Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

www.stocktitan.net/news/PLRX/pliant-therape...

0 0 0 0